Alpha Tau Medical Ltd. (DRTS) 股票分析

公司概述

Alpha Tau Medical Ltd. operates as a clinical-stage oncology therapeutics company dedicated to the research, development, and commercialization of diffusing alpha-emitters radiation therapy, specifically designed for the treatment of solid tumors. The company functions within the Healthcare sector and the Biotechnology industry, positioning itself to leverage advancements in nuclear medicine for oncological applications. As of the latest available data, the entity maintains a market capitalization of $646.87 million and employs a workforce of 121 individuals across its operations. The current market capitalization of $646.87 million, combined with reported annual revenue figures that are currently unavailable for calculation, suggests a valuation that reflects the high-risk, high-reward nature typical of clinical-stage biotechnology firms where significant capital investment is required before commercial product realization.

财务健康

The company's financial statements for the trailing twelve months show a net income of $-42,627,000 and an EBITDA of $-41,056,000, while specific revenue figures are not disclosed in the provided dataset. The substantial gap between the reported negative net income and the slightly less negative EBITDA reveals a cost structure heavily influenced by significant non-operating expenses or interest costs that erode the operating earnings before tax and interest. Free cash flow stands at $-19,703,876, indicating that the company is currently consuming cash to fund its research and development activities rather than generating liquidity from operations. This negative free cash flow flow is a common characteristic of clinical-stage biotechs but necessitates careful management of the $73.13 million in available cash reserves. The company reports a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, all of which indicate that the business has not yet achieved profitability or that standard accounting treatments for early-stage development have resulted in zero margins prior to commercial sales. On the liability side, the company holds $73.13 million in cash against $13.73 million in debt, resulting in a debt-to-equity ratio of 17.80, which suggests a highly leveraged capital structure relative to equity rather than a conservative balance sheet. Despite the high debt-to-equity figure, the current ratio of 7.45 indicates strong short-term liquidity, as current assets significantly exceed current liabilities. Furthermore, the return on equity is -61.0% and the return on assets is -27.6%, metrics that reveal that management has not yet been effective in generating positive returns on the capital deployed, a status expected for a company still in the clinical trial phase.

估值评估

Valuation multiples for the company present a complex picture, with a trailing P/E ratio that is not applicable due to negative earnings and a forward P/E of -17.26. The negative forward P/E implies that the market expects earnings to remain negative or that valuation models relying on price-to-earnings are not currently meaningful for this asset. The price-to-book ratio is recorded at 8.39, indicating that the market values the company at a significant premium over its net book value, likely reflecting the intangible value of its proprietary Alpha-DaRT technology and intellectual property. Alternative valuation metrics include a price-to-sales ratio that is not applicable and an EV/EBITDA of -14.31, which suggests that traditional enterprise value multiples are distorted by the company's current lack of profitability and negative earnings. The stock's price action has ranged between a 52-week high of $8.60 and a 52-week low of $2.43, meaning the current trading price sits at a specific point within this volatility range relative to the recent historical extremes. The beta of 1.05 indicates that the stock's price volatility is slightly higher than the broader market, moving in tandem with general market fluctuations but with a slight upward bias in sensitivity.

Growth & Income

Revenue growth year-over-year and earnings growth year-over-year are both listed as not applicable in the available data, preventing a direct comparison of earnings growth rates against revenue growth rates at this stage. As a non-dividend payer, the company reports a dividend yield of not applicable and a payout ratio of 0.0%, meaning the entity reinvests all available earnings and cash reserves back into its research and development pipeline rather than distributing income to shareholders. The absence of a dividend payout is consistent with the company's life cycle stage, where capital preservation and funding for clinical trials take precedence over shareholder income distributions. Overall, the growth and income profile is characterized by a focus on capital allocation for long-term clinical development rather than immediate financial returns or dividend income for investors.